Paul Leyerle
About Paul Leyerle
Paul Leyerle is a Sr. Global Trial Specialist at Bristol Myers Squibb with expertise in CAR-T cell therapy and a background in oncology clinical trials.
Current Position at Bristol Myers Squibb
Paul Leyerle is currently serving as a Sr. Global Trial Specialist at Bristol Myers Squibb. Since joining the company in March 2016, he has been heavily involved in global clinical trials. His role focuses on managing and overseeing trials that aim to bring innovative medical treatments to market.
Experience with CAR-T Cell Therapy
Paul Leyerle has significant experience working with CAR-T cell therapy, a revolutionary treatment in the field of oncology. This type of therapy harnesses the power of a patient's own immune cells to fight cancer, representing a significant advancement in cancer treatment. His involvement in this area places him at the forefront of cutting-edge medical research.
Previous Employment at Celgene and Juno Therapeutics
Before Bristol Myers Squibb, Paul Leyerle worked at Celgene and Juno Therapeutics. These companies have made notable contributions to medical science, particularly in oncology. Both companies were later acquired by Bristol Myers Squibb, providing him with a continuity in his career trajectory within the same overarching organization.
Educational Background
Paul Leyerle has an educational background rooted in the University of Washington and Whatcom Community College. His academic credentials from these institutions have equipped him with the foundational skills and knowledge necessary for his career in clinical trials and medical research.
Professional Base in Seattle, US
Based in Seattle, US, Paul Leyerle contributes to global clinical trials from this hub. Seattle is known for its robust biotechnology sector, offering a conducive environment for leading-edge clinical research and trials.